Treatment of Relapsed/Refractory CLL Patients With PI3Kδ Inhibitor and Anti‐CD20 Antibody Rapidly Decreases Tumor Burden but Could Induce Resistance
- 2 January 2025
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 100 (3) , 523-526
Abstract
No abstract availableKeywords
Funding Information
- TG Therapeutics
This publication has 6 references indexed in Scilit:
- Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemiaBlood Advances, 2024
- Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemiaBlood Advances, 2023
- Rituximab induced cytokine release with high serum IP-10 (CXCL10) concentrations is associated with infusion reactionsLeukemia Research, 2023
- Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What's Past Is Prologue” (Shakespeare)Clinical Cancer Research, 2021
- Macrophage hypophagia as a mechanism of innate immune exhaustion in mAb-induced cell clearanceBlood, 2020
- Cellular Cytotoxicity of Next-Generation CD20 Monoclonal AntibodiesCancer Immunology Research, 2018